Please try another search
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Name | Age | Since | Title |
---|---|---|---|
Vlad Ratziu | - | - | Member of Scientific Advisory Board |
Arun J. Sanyal | - | - | Member of Scientific Advisory Board |
Shmuel Nir | 59 | 2007 | Independent Director |
Amir Poshinski | 60 | 2020 | Independent Director |
David Sidransky | 61 | 2014 | Lead Independent Director |
Allen Baharaff | 56 | 2000 | Co-Founder, President, CEO & Chairman |
José María Mato de la Paz | - | - | Member of Scientific Advisory Board |
Shomron Ben-Horin | - | - | Member of Scientific Advisory Board |
Scott L. Friedman | - | - | Member of Scientific Advisory Board |
Carol L. Brosgart | 72 | 2017 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review